Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | TACR3 | P29371 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10940755 | 0.85 | CYP2C19 (0.39) | CYP2C19MAPTTSHRCYP2C9KDM4E | |
| SCHEMBL7626939 | 0.84 | CYP2C19 (0.36) | CYP2C19MAPTTSHRCYP2C9KDM4E | |
| SCHEMBL5406587 | 0.84 | CYP4F2 (0.32) | CYP4F2CYP4A11 | |
| SCHEMBL8859121 | 0.82 | PTPN1 (0.31) | MAPTTSHRCYP2C9 | |
| SCHEMBL4349604 | 0.82 | CYP2C19 (0.34) | CYP2C19MAPTTSHRCYP2C9KDM4E | |
| SCHEMBL17779666 | 0.81 | CYP2C19 (0.36) | CYP2C19MAPTTSHRCYP2C9KDM4E | |
| SCHEMBL14338624 | 0.80 | ABHD6 (0.30) | — | |
| SCHEMBL1417675 | 0.80 | CYP4F2 (0.37) | CYP2C19MAPTTSHRCYP2C9KDM4E | |
| SCHEMBL4811675 | 0.80 | MAPT (0.41) | CYP2C19MAPTTSHRCYP2C9KDM4E | |
| SCHEMBL14799327 | 0.80 | CYP2C19 (0.33) | CYP2C19MAPTTSHRCYP2C9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106459003-B | Pyrazole amide derivatives | 帝人制药株式会社 | 2019-06-21 | — | — | CN | disclosed |
| US-10233146-B2 | Acetylenic cyanoenones as therapeutics for inflammation and carcinogenesis | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-03-19 | — | — | US | disclosed |
| US-10233146-B2 | Acetylenic cyanoenones as therapeutics for inflammation and carcinogenesis | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180134654-A1 | ACETYLENIC CYANOENONES AS THERAPEUTICS FOR INFLAMMATION AND CARCINOGENESIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134654-A1 | ACETYLENIC CYANOENONES AS THERAPEUTICS FOR INFLAMMATION AND CARCINOGENESIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134654-A1 | ACETYLENIC CYANOENONES AS THERAPEUTICS FOR INFLAMMATION AND CARCINOGENESIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2018-05-17 | — | — | US | disclosed |
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| CN-106459003-A | Pyrazole amide derivatives | 帝人制药株式会社 | 2017-02-22 | — | — | CN | disclosed |
| EP-3110810-A1 | PYRAZOLE AMIDE DERIVATIVE | Teijin Pharma Limited (JP) | 2017-01-04 | — | — | EP | disclosed |
| WO-2016168450-A1 | ACETYLENIC CYANOENONES AS THERAPEUTICS FOR INFLAMMATION AND CARCINOGENESIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2016-10-20 | — | — | WO | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015129926-A1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-09-03 | — | — | WO | disclosed |
| US-5973080-A | MODIFIED DIVINYLBENZENE-STYRENE COPOLYMER | ELF AQUITAINE PRODUCTION (FR) | 1999-10-26 | — | — | US | disclosed |
| US-5817716-A | MODIFIED DIVINYLBENZENE-STYRENE COPOLYMER | ELF AQUITAINE PRODUCTION (FR) | 1998-10-06 | — | — | US | disclosed |
| US-5726253-A | REACTING DIVINYLBENZENE-STYRENE RESIN WITH CHLOROFORMAMIDINIUM CHLORIDE IN BASE | ELF AQUITAINE PRODUCTION (FR) | 1998-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134654-A1 | ACETYLENIC CYANOENONES AS THERAPEUTICS FOR INFLAMMATION AND CARCINOGENESIS | ACOX3, ACOT7, ACOX1 | CYP2C19 2668/4885MAPT 4660/4885TSHR 807/4885 |
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | CYP2C19 996/4885MAPT 3584/4885TSHR 873/4885 |
| US-10233146-B2 | Acetylenic cyanoenones as therapeutics for inflammation and carcinogenesis | ACOX3, ACOT7, ACOX1 | CYP2C19 2684/4885MAPT 4657/4885TSHR 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.